|
| |
UCB S.AUCB is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories.VisionTo build a global biopharmaceutical leader, based on unique blending of innovation, entrepreneurship and proven experience bringing to specialists first, new medicines to treat patients suffering from severe diseases.ValuesPassion and PerformanceWe are passionate about what we do and about UCB's performance.
| Contact Details: |
| Allée de la Recherche, 60 |
| Brussels |
| |
| 1070 |
| Belgium |
| Tel: | 32/2/559.99.99 |
| Fax: | 32/2/559.99.00 |
| Email: | contactucb@UCB-Group.com |
| WWW: | www.ucb-group.com/
|
| |
Recent Publications by UCB S.A: |  |
Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease.
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory illness... | 10th October, 2009
| UCB S.A., Andelecht, Belgium.
| Aliment Pharmacol Ther. 2009 May 1;29(9):1032-41.
DOI Direct Link |
Visualization of SV2A conformations in situ by the use of Protein Tomography.
The synaptic vesicle protein 2A (SV2A), the brain-binding site of the... | 28th October, 2008
| Department of Molecular and Cellular Sciences, UCB S.A., Granta Park,
| Biochem Biophys Res Commun. 2008 Oct 31;375(4):491-5. Epub 2008 Aug 8.
DOI Direct Link |
2,6-Quinolinyl derivatives as potent VLA-4 antagonists.
A new series of 2,6-quinolinyl derivatives was prepared leading to potent... | 25th April, 2007
| UCB S.A., R&D, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium.
| Bioorg Med Chem Lett. 2007 Jan 1;17(1):142-6. Epub 2006 Oct 10.
DOI Direct Link |
Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.
High-throughput screening of the UCB sample collection identified the... | 25th April, 2007
| CNS Molecular and Cellular Biology, Centre for CNS Innovation, UCB S.A.,
| Bioorg Med Chem Lett. 2007 Jan 1;17(1):272-7. Epub 2006 Oct 5.
DOI Direct Link |
The connexin 36 blockers quinine, quinidine and mefloquine inhibit cortical spreading depression in a rat neocortical slice model in vitro.
A protocol for inducing cortical spreading depression (SD) on rat... | 3rd February, 2007
| UCB S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.
| Brain Res Bull. 2006 Dec 11;71(1-3):23-8. Epub 2006 Aug 11.
DOI Direct Link |
→View more UCB S.A research publications. |
Press Releases on UCB S.A:
|
 |
| Reportlinker Adds Regenerative Medicines: Bone and Joint Applications |
3rd November, 2009 |
Reportlinker |
NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Regenerative Medicines: Bone and Joint Applications
http://www.reportlinker
|
| Shire Continues to Deliver Excellent Growth From Core Products |
30th October, 2009 |
|
DUBLIN, October 30 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty
biopharmaceutical company, announces results for the three months to
September 30, 2009.
Q3 2009
|
| Shire begins the year with a strong performance |
30th April, 2009 |
|
PHILADELPHIA and DUBLIN, April 30 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty
biopharmaceutical company, announces results for the three months to March
31, 2009.
|
| Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets |
31st July, 2008 |
Barr Pharmaceuticals, Inc. |
MONTVALE, N.J., July 31 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals,
Inc. (NYSE: BRL) today confirmed that its subsidiaries, Barr Laboratories,
Inc. and PLIVA-Hrvatska D.O.O., have initiated a
|
| US FDA Grants Pediatric Exclusivity for UCB's Keppra(R) |
6th June, 2008 |
UCB |
SMYRNA, Ga., June 6 /PRNewswire/ -- UCB announced today that the US Food
and Drug Administration (FDA) has granted pediatric exclusivity for Keppra(R)
(levetiracetam). The decision was based on
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 16 individuals from UCB S.A using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 257 times since April 2007, the link to the organisation's website has been followed 39 times Search for more companies in Brussels Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for UCB S.A |
